Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06613217 · ClinicalTrials.gov registry record · Phase 1
Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
A Phase 1 study of Relapsed Adult AML, sponsored by Pacylex Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT06613217 is a Phase 1 study of Relapsed Adult AML that is actively recruiting participants, run by Pacylex Pharmaceuticals. The registered enrollment target is 35 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06613217, a Phase 1 study of Relapsed Adult AML, is actively recruiting participants, sponsored by Pacylex Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a dose-finding study of oral zelenirstat (PCLX-001) in patients with R/R AML. There are two parts to the study: Dose Escalation and Dose Expansion.
Conditions Studied
Interventions
- DRUG zelenirstat
Study Locations (1)
Texas
- MD Anderson Cancer Centre - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06613217
The ClinicalTrials.gov registry entry for NCT06613217 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacylex Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed Adult AML appearing as the primary indexed condition, and to 1 intervention - of which zelenirstat is the first listed.
NCT06613217 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06613217 about?
NCT06613217 is a clinical study titled "Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia". This is a dose-finding study of oral zelenirstat (PCLX-001) in patients with R/R AML. There are two parts to the study: Dose Escalation and Dose Expansion.
What is the current status of trial NCT06613217?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2025-03-03. Estimated completion is 2026-09-01.
What conditions does trial NCT06613217 study?
This clinical trial studies the following conditions: Relapsed Adult AML.
What interventions are being tested in trial NCT06613217?
The interventions under investigation include: zelenirstat (DRUG).
Who is sponsoring clinical trial NCT06613217?
This trial is sponsored by Pacylex Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06613217 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed Adult AML
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.